<code id='B9938FD677'></code><style id='B9938FD677'></style>
    • <acronym id='B9938FD677'></acronym>
      <center id='B9938FD677'><center id='B9938FD677'><tfoot id='B9938FD677'></tfoot></center><abbr id='B9938FD677'><dir id='B9938FD677'><tfoot id='B9938FD677'></tfoot><noframes id='B9938FD677'>

    • <optgroup id='B9938FD677'><strike id='B9938FD677'><sup id='B9938FD677'></sup></strike><code id='B9938FD677'></code></optgroup>
        1. <b id='B9938FD677'><label id='B9938FD677'><select id='B9938FD677'><dt id='B9938FD677'><span id='B9938FD677'></span></dt></select></label></b><u id='B9938FD677'></u>
          <i id='B9938FD677'><strike id='B9938FD677'><tt id='B9938FD677'><pre id='B9938FD677'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:leisure time    Page View:62
          Joaquin Duato -- health policy coverage from STAT
          Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

          WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

          The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

          advertisement

          “​​The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Results on Novartis prostate cancer therapy could expand its use
          Results on Novartis prostate cancer therapy could expand its use

          TheNovartisboothatESMO2023inMadrid.AndrewJoseph/STATMADRID—ResultspresentedMondaycouldexpandtheuseof

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          How AI can help patients find reliable information about doctors

          AdobeAlmostassoonasChatGPTwasreleasedtothepublic,doctorsbeganfocusingonhowtheycouldharnessartificial